| |||||||||||||||||||||
簡介
鐮狀細胞貧血症為遺傳性(先天性)的血液疾病，血液中的紅血球形狀異常。主要的前兆、症狀為貧血和發育遲緩、視野障礙、疼痛、頻繁感染感染疾病等。主要的治療方法，有抗生素和止痛藥、輸血、幹細胞移植等。
本報告提供全球各國的鐮形血球貧血症治療用的開發中產品的開發情形相關分析、產品開發與上市的最新趨勢，及臨床實驗各階段的產品一覽，再加上主要企業簡介、主要藥物概要、最新的產業趨勢等資訊。 Before the financial crisis, dealer market-making held a powerful place in the nation’s biggest investment banks. The fresh-out-of-college traders that shuffled in and out of Manhattan bank buildings each day handled the banks' inventories of bonds worth hundreds of millions of dollars, which they used as starting capital to make their own trades, says Lawrence McDonald, a former Lehman Bros. corporate bond trader. The holdings, which were used to make markets for each type of corporate security, would fit into two categories, or books.
“The front book is the facilitation book. That’s the book for client liquidity. The back book is your prop position. That book was responsible for a lot of profits on the Street in 2007, and that today pretty much doesn’t exist,” said McDonald, who authored A Colossal Failure of Common Sense, a bestseller about the bank's demise.
That system crumbled in the years after the financial crisis. The facilitation books shrank in size while the proprietary trading books became virtually non-existent. Dealer balance sheet sizes fell to a fraction of what they once were.
The smaller amount that dealers hold on their books means they can’t unconditionally buy bonds that investors are trying to sell, especially in large blocks
| |||||||||||||||||||||
No comments:
Post a Comment